Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.
about
Oral insulinA review on the strategies for oral delivery of proteins and peptides and their clinical perspectivesThe plant decapeptide OSIP108 prevents copper-induced apoptosis in yeast and human cellsExploring patients' perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative studyA discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management.Reducing injection pain in children and adolescents with diabetes: a review of indwelling catheters.Strategies to improve oral drug bioavailability.Approaches for enhancing oral bioavailability of peptides and proteinsOral insulin and buccal insulin: a critical reappraisal.Strategies for enhanced peptide and protein delivery.Systemic delivery of biotherapeutics through the lung: opportunities and challenges for improved lung absorption.Polymer-drug conjugates: recent progress on administration routes.Advances in oral macromolecular drug delivery.Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis.Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes.Materials and methods for delivery of biological drugs.Hydrophobic ion pairing of an insulin-sodium deoxycholate complex for oral delivery of insulin.Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation.A valuation of patients' willingness-to-pay for insulin delivery in diabetes.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.Oral insulin delivery: existing barriers and current counter-strategies.Novel alginate gel microspheres produced by impinging aerosols for oral delivery of proteins
P2860
Q21198761-5F3EAF8D-3D42-48E4-8F42-A269008F0605Q26744008-5244AC4E-DE83-4B55-A37D-D24BE08517A0Q33709655-6CCF18A6-E930-4375-BB11-225F8FD6AA1AQ34041978-03FFC7BC-F749-4990-9D19-E59BC9A58894Q34555138-78D8D60A-E3CA-443F-99D6-5D9570FCAF7AQ35800246-D7333F1B-03CC-4B92-ABD1-8542EBEB6597Q36316751-7A5B0C0F-E1AC-4330-991A-556B543F68EDQ36922557-612A9365-07E2-464C-9F0C-E3559D3DEAC1Q37689833-361F0031-98A3-4D7C-A4A7-5CB5A31A9C9BQ38104408-2693893D-C2AB-4485-9AD7-C469DF2DB0DEQ38168594-251388B1-A8A5-4DB9-A312-3C6A0F8F9E78Q38206549-6BD10471-16E0-43E8-992B-960F309D95D0Q38235506-32830788-DFA9-4977-AED6-02BDEBE7F5D2Q38536492-E29676BC-0DC5-43EC-8791-EF200FAFE088Q38847705-15D813E0-9401-491B-B6E5-677758594DE9Q38987392-B13CD30E-4BF4-40D8-9EF2-338F11CAA9ABQ39599106-E7089315-1EE8-49F1-BA23-D26C24284B53Q43180563-42F9D6A8-C609-44AD-8730-8A6D3F3C0DDEQ45924945-C0394674-A1E3-4B8B-9769-08E050972280Q47590580-354894EA-4FE3-47E8-A801-E31C79034762Q48203947-61E4B3C2-2146-4200-8A79-6DEE6D644E44Q57382753-9C4D1F95-EE7F-41FC-850A-BC0A511FDE33
P2860
Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Oral insulin product hexyl-ins ...... stabilization effects of HIM2.
@en
Oral insulin product hexyl-insulin monoconjugate 2
@nl
type
label
Oral insulin product hexyl-ins ...... stabilization effects of HIM2.
@en
Oral insulin product hexyl-insulin monoconjugate 2
@nl
prefLabel
Oral insulin product hexyl-ins ...... stabilization effects of HIM2.
@en
Oral insulin product hexyl-insulin monoconjugate 2
@nl
P2093
P1476
Oral insulin product hexyl-ins ...... stabilization effects of HIM2.
@en
P2093
Gordana Kosutic
J Gordon Still
R G McAllister
Stephen Clement
P304
P356
10.1089/152091502760306544
P577
2002-01-01T00:00:00Z